It found that GLP-1s reduced the risk of alcohol-related disorders in those with no history of substance use by 18% and of using cannabis (14%), cocaine (20%), nicotine (20%) and opioids (25%), compared with those on other sodium-glucose cotransporter-2 drugs also used to treat diabetes
At the 4-month mark, participants taking pramlintide experienced weight loss ranging from 3.449 to 6.1 kg, while the placebo group lost only 2.449 kg
Naltrexone has been found to reduce cravings and heavy drinking, while acamprosate helps with abstinence
Alternativas y ajustes si las inyecciones son muy dolorosas Para pacientes que experimentan molestias significativas persistentes a pesar de la tcnica ptima, existen varias opciones que pueden discutirse con el proveedor de atencin mdica
Individual tolerance varies significantly
Niraj Choudhary, MD , for effective weight loss at Primary Care of Clear Lake